Core Viewpoint - Avacta Group Plc is presenting data on faridoxorubicin in Phase Ib trials for patients with salivary gland cancers, highlighting the innovative pre|CISION drug delivery system that enhances treatment efficacy while minimizing toxicity [2][3]. Group 1: Drug Delivery System - The pre|CISION program utilizes a FAP-activated drug delivery mechanism that allows a toxic drug to remain inactive in the bloodstream and normal tissues, becoming active only at the tumor site [3]. - The mechanism involves the binding of a pre|CISION peptide that masks the toxic payload, with drug release triggered by fibroblast activation protein (FAP) found in tumor-supporting cells [3]. Group 2: Treatment Benefits - This targeted approach reduces exposure of normal tissues and bone marrow to toxic effects, enabling prolonged treatment durations compared to conventional therapies [4]. - Enhanced survival rates have been observed due to the ability to administer treatment beyond the limits of traditional oncology drugs [4].